VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen

The anti-CSPG4 monoclonal antibodies (mAbs) have shown anti-tumor activity and therapeutic potential for treating breast cancer. In addition, CSPG4 is a dominant tumor-associated antigen that is also involved in normal-tissue development in humans. Therefore, the potential for off-tumor activity rem...

Descripción completa

Detalles Bibliográficos
Autores principales: Nounamo, Bernice, Jousheghany, Fariba, Siegel, Eric Robb, Post, Steven R., Kelly, Thomas, Ferrone, Soldano, Kieber-Emmons, Thomas, Monzavi-Karbassi, Behjatolah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917008/
https://www.ncbi.nlm.nih.gov/pubmed/36768830
http://dx.doi.org/10.3390/ijms24032506

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917008/
https://www.ncbi.nlm.nih.gov/pubmed/36768830
http://dx.doi.org/10.3390/ijms24032506

Ejemplares similares